Skip to main content

Table 2 Serum concentrations of vascular markers in patients with systemic sclerosis (SSc) at baseline and in controls

From: Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1

Serum constituent Controls (n = 20) SSc patients at baseline (n = 40) P (Mann–Whitney test)
sVCAM-1 (pg/ml) 465.5 (378–619) 712 (362–1034) P < 0.0001
Carbonyl residues (nmol/mg protein) 0.34 (0.15–0.64) 0.83 (0.37–1.48) P < 0.0001
AOPP (μmol/l of chloramine-T equivalents) 75.5 (21–91) 109.1 (50–281) P < 0.0001
VEGF (pg/ml) 221 (19–499) 573.5 (26–1915) P = 0.0001
sVEGFR-1 (pg/ml) 19 (8–73) 45 (10–1140) P = 0.0025
  1. Values are median (range) of serum concentrations in patients or controls. AOPP, advanced oxidation protein products; sVCAM-1, soluble vascular cell adhesion molecule 1; sVEGFR-1, soluble VEGF receptor 1; VEGF, vascular endothelial growth factor.